1/153
Comprehensive practice flashcards covering the pathophysiology, clinical manifestations, diagnostics, and interprofessional nursing management of coronary artery disease, acute coronary syndromes, heart failure, and aortic aneurysms.
Coronary Artery Disease (CAD)
A blood vessel disorder in the category of atherosclerosis characterized by lipid and fibrous plaque accumulation within coronary arteries, representing the leading cause of death in the United States.
Atherosclerosis
A disease process characterized by the progressive accumulation of lipid deposits, fibrous tissue, and calcium within arterial walls, leading to lumen narrowing and decreased tissue perfusion.
Chronic Endothelial Injury
The initial stage in the development of atherosclerosis caused by damage to the arterial endothelium from mechanical or biochemical insults, initiating an inflammatory vascular response.
Etiologies of Endothelial Injury
Precipitating insults that damage the vascular endothelium, including hypertension, tobacco use, hyperlipidemia, hyperhomocysteinemia, diabetes mellitus, infections, and circulating toxins.
Fatty Streak
The earliest macroscopic lesion of atherosclerosis, characterized by lipid accumulation that migrates into smooth muscle cells, creating a yellow appearance within the vessel wall.
Fatty Streak Clinical Presentation
An early vascular lesion typically present by age 20 that is potentially reversible or slowed through aggressive lowering of low-density lipoproteins (LDL).
Fibrous Plaque
A progressive atherosclerotic lesion where collagen covers the fatty streak, producing a greyish-white narrowing of the vessel lumen that reduces downstream blood flow and can develop fissures.
Fibrous Plaque Appearance and Timeline
A collagen-encapsulated atherosclerotic lesion that typically appears within coronary vessels by age 30 and presents macroscopically with a greyish-white color.
Complicated Lesion
A critical, dangerous stage of atherosclerosis characterized by plaque rupture, thrombus formation, and significant lumen narrowing or total vessel occlusion, severely compromising oxygen perfusion.

Stages of Atherosclerosis
The progressive four-stage pathophysiologic sequence comprising chronic endothelial injury, fatty streak development, fibrous plaque formation, and the unstable complicated lesion.

Collateral Circulation
The arterial network of new channels developed by the body to bypass chronic, partial coronary artery blockages and maintain distal myocardial perfusion.
Modifiable Risk Factors for CAD
Controllable factors that accelerate atherosclerosis, including hypertension, tobacco use, elevated low-density lipoprotein levels, obesity, and unmanaged diabetes.
Non-Modifiable Risk Factors for CAD
Inherent individual risk characteristics for coronary artery disease that cannot be altered, including advanced age, male gender, and family history or genetic predisposition.
Hyperlipidemia in CAD
Elevated circulating serum lipids, particularly high levels of low-density lipoproteins (LDL), that infiltrate injured endothelium and form vascular plaques.
Hyperhomocysteinemia
An elevated level of homocysteine in the blood that contributes directly to chronic vascular endothelial injury and accelerates atherosclerosis.
Tobacco Use in CAD Pathophysiology
A major modifiable risk factor that causes direct chemical endothelial injury, increases sympathetic tone, and promotes coronary platelet aggregation.
Hypertension in CAD Pathophysiology
Sustained high vascular hydrostatic pressure that causes chronic mechanical shear stress and endothelial injury, predisposing arteries to lipid infiltration.
Diabetes Mellitus in CAD Pathophysiology
A metabolic disorder that accelerates atherosclerosis by inducing endothelial injury, hyperlipidemia, and altered platelet function.
Chronic Stable Angina
Intermittent chest discomfort characterized by predictable onset, a duration of 5–15 minutes, and relief following rest or the administration of sublingual nitroglycerin.
Precipitating Factors of Angina
Triggers that increase myocardial oxygen demand above available supply, including physical exertion, temperature extremes, strong emotions, consumption of heavy meals, and tobacco use.
Sublingual Nitroglycerin Protocol
The acute dosing guideline directing patients to take one sublingual tablet every 5 minutes for up to 3 doses; if pain persists unresolved, emergency medical services (911) must be called immediately.
Phosphodiesterase Inhibitor Contraindication
The strict avoidance of concurrent administration of nitroglycerin with phosphodiesterase-5 inhibitors like sildenafil due to the risk of profound, life-threatening hypotension.
Angina at Rest
Unpredictable chest discomfort occurring without physical exertion or provocation, indicating an unstable coronary condition that requires urgent hospital evaluation.
Therapeutic Lifestyle Changes for CAD
Non-pharmacologic primary and secondary interventions including dietary modifications (low saturated fat, low cholesterol), regular physical activity, weight management, and complete tobacco cessation.
Acute Coronary Syndrome (ACS)
An umbrella medical term encompassing an urgent spectrum of myocardial ischemia including unstable angina, Non-ST-Segment-Elevation Myocardial Infarction, and ST-Segment-Elevation Myocardial Infarction.

Acute Coronary Syndrome Continuum
The clinical progression where worsening coronary atherosclerosis destabilizes from chronic stable angina into unstable angina, NSTEMI, or STEMI.
Myocardial Ischemia
A condition characterized by insufficient arterial blood flow and oxygen delivery to cardiac myocytes that is typically reversible upon timely reperfusion.
Myocardial Infarction (MI)
Irreversible necrosis and death of myocardial tissue resulting from prolonged, severe deprivation of oxygen and arterial blood supply.
Timeframe of Myocardial Hypoxia
The rapid cellular physiological event where cardiac muscle becomes severely hypoxic within 10 seconds of total coronary artery occlusion.
Anaerobic Metabolism in Ischemia
The compensatory, oxygen-deprived metabolic pathway activated during acute coronary occlusion that leads to lactic acid accumulation and metabolic acidosis.
Myocardial Cell Viability Limit
The critical time threshold of approximately 20 minutes during total ischemia after which irreversible myocardial cell death occurs if blood flow is not restored.
Reperfusion Restoration Window
The prompt therapeutic restoration of coronary blood flow within 20 minutes that restores aerobic metabolism, re-establishes contractility, and rescues ischemic myocytes.
Plaque Deterioration Mechanism
The acute event wherein a previously stable atheromatous plaque ruptures, exposing thrombogenic core lipids to platelets and initiating thrombus aggregation.
Unstable Angina (UA)
Chest discomfort caused by partial coronary occlusion that occurs at rest, exhibits a new onset or crescendo pattern, and is not associated with elevated serum cardiac biomarkers.
Non-ST-Segment-Elevation Myocardial Infarction (NSTEMI)
Myocardial necrosis caused by partial coronary occlusion characterized by elevated serum cardiac biomarkers without acute ST-segment elevation on a 12-lead ECG.
ST-Segment-Elevation Myocardial Infarction (STEMI)
Severe transmural myocardial necrosis resulting from complete, total coronary artery occlusion that produces classic ST-segment elevation across affected ECG leads and biomarker elevations.

Left Anterior Descending (LAD) Coronary Artery Occlusion
An occlusion of the anterior descending coronary artery that causes anterior wall myocardial infarction, frequently compromising left ventricular ejection.
Circumflex Coronary Artery
A major branch of the left coronary artery supplying the lateral and posterior walls of the left ventricle and portions of the cardiac conduction system.
Right Coronary Artery (RCA)
The coronary artery supplying the right atrium, right ventricle, inferior left ventricular wall, and the sinoatrial and atrioventricular nodes.
Classic Pain Manifestations of MI
Severe, immobilizing chest pressure, heaviness, tightness, or burning that persists unrelieved by rest or nitroglycerin and commonly radiates to the neck, jaw, arms, or back.
Atypical MI Presentation
Subtle, non-classic manifestations of myocardial infarction commonly seen in women, older adults, and individuals with diabetes, presenting as epigastric discomfort, dyspnea, nausea, or profound fatigue.
Sympathetic Nervous System Stimulation in MI
The acute neurohormonal reflex response to severe ischemic pain that triggers catecholamine release, resulting in diaphoresis, peripheral vasoconstriction, cool/clammy skin, and transient tachycardia.
Gastrointestinal Symptoms of MI
Nausea and vomiting resulting from vasovagal reflexes or reflex stimulation of the medullary vomiting center secondary to severe cardiac ischemic pain.
Fever Manifestation in MI
A low-grade systemic temperature elevation that develops within 24 to 48 hours following acute myocardial infarction secondary to widespread myocardial necrosis and inflammatory cytokine release.
Ventricular Gallops (S3 and S4)
Abnormal heart sounds heard on cardiac auscultation post-MI reflecting left ventricular compliance defects, elevated filling pressures, or acute ventricular dysfunction.
Dysrhythmias Complication of MI
The most frequent acute complication following acute myocardial infarction, caused by electrical instability, ischemic injury to conduction pathways, and altered electrolyte exchange.
Ventricular Fibrillation (V-Fib)
A chaotic, lethal ventricular rhythm frequently triggered during acute myocardial infarction that causes total cessation of effective cardiac output and requires immediate defibrillation.
Cardiogenic Shock
A severe state of end-organ hypoperfusion occurring when extensive left ventricular infarction leaves the myocardium unable to generate adequate cardiac output to sustain vital functions.
Papillary Muscle Dysfunction
Ischemic injury to papillary structures causing new-onset mitral valve regurgitation, audible as an apical systolic murmur and causing rapid pulmonary congestion.
Papillary Muscle Rupture
A catastrophic mechanical tear of the infarcted papillary muscle producing massive acute mitral regurgitation, acute pulmonary edema, and sudden cardiogenic collapse.
Ventricular Septal Wall Rupture
A mechanical rupture within the interventricular septum post-MI that produces a harsh holosystolic murmur, a left-to-right shunt, and rapid hemodynamic decompensation.
Left Ventricular Aneurysm
A structural complication where the thinned, infarcted ventricular wall bulges outward during systole, harboring thrombi, inducing dysrhythmias, and worsening heart failure.
Acute Pericarditis Post-MI
Inflammation of the pericardial sac occurring 2 to 3 days post-infarction, characterized by pleuritic chest pain relieved by sitting forward, generalized ST elevation, and a friction rub.
Dressler Syndrome
An autoimmune-mediated pericarditis accompanied by fever and joint pain that develops 1 to 8 weeks after myocardial infarction.
Medical Management of Dressler Syndrome
The administration of high-dose aspirin as the initial treatment of choice to suppress autoimmune pericardial inflammation and alleviate arthralgia.
Acute Inflammatory Phase of MI Healing
The cellular response within the initial 24 hours post-MI where neutrophils and monocytes infiltrate the necrotic zone to degrade and clear dead myocardial tissue.
Proteolytic Enzymes in Myocardial Repair
Digestive enzymes released by infiltrating neutrophils and macrophages that clear necrotic cellular debris while temporarily thinning the myocardial wall.
Myocardial Vulnerability Window
The period between 10 and 14 days post-MI when developing scar tissue remains structurally weak, making the ventricular wall particularly vulnerable to physical stress.
Scar Tissue Replacement Timeline
The healing milestone achieved approximately 6 weeks following myocardial infarction where permanent, non-contractile collagenous scar tissue completely replaces necrotic myocardium.
Ventricular Remodeling Post-MI
The compensatory structural alteration whereby non-infarcted myocardium dilates and hypertrophies in an attempt to maintain stroke volume, often ultimately predisposing to heart failure.

Serum Cardiac Biomarkers Timeline
The characteristic diagnostic patterns of rise, peak, and clearance for cardiac troponin, CK-MB, and myoglobin following acute myocardial cell necrosis.
Cardiac-Specific Troponin (cTn)
The gold-standard biomarker of myocardial injury that begins rising within hours of infarction, peaks at 15 to 24 hours, and remains detectable for 10 to 14 days.
Creatine Kinase-MB (CK-MB)
A cardiac isoenzyme biomarker that rises within 3 to 6 hours after myocardial necrosis, reaches peak levels at 15 to 24 hours, and returns to baseline within 2 to 3 days.
Myoglobin Biomarker
An early serum protein biomarker that rises within 1 to 4 hours following cardiac injury and peaks around 4 hours, though it lacks cardiac tissue specificity.
ST-Segment Elevation on 12-Lead ECG
An electrocardiographic finding indicating acute, transmural myocardial injury and total coronary occlusion requiring immediate emergent reperfusion therapy.
ST-Segment Depression and T-Wave Inversion
Electrocardiographic indicators demonstrating subendocardial myocardial ischemia or Non-ST-Segment-Elevation Myocardial Infarction.
Emergent Percutaneous Coronary Intervention (PCI)
The primary catheter-based invasive reperfusion strategy used to rapidly recanalize an occluded coronary vessel in patients presenting with STEMI.

Door-to-Balloon Benchmark for STEMI
The strict quality-of-care standard requiring patients presenting with confirmed STEMI to undergo coronary balloon inflation within 90 minutes of hospital arrival.
Bare-Metal Stents vs. Drug-Eluting Stents
Intracoronary endovascular scaffolds deployed during PCI, where drug-eluting models are coated with antiproliferative agents to prevent in-stent restenosis.
Door-to-Needle Benchmark
The performance standard requiring intravenous administration of thrombolytic therapy within 30 minutes of hospital arrival when emergent PCI is unavailable.
Coronary Artery Bypass Graft (CABG) Surgery
Surgical revascularization wherein conduits (such as saphenous veins or internal mammary arteries) are grafted to bypass multi-vessel or severe left main coronary disease.
Dual Antiplatelet Therapy (DAPT)
The combined pharmacologic regimen of aspirin along with a P2Y12 platelet receptor inhibitor (such as clopidogrel) prescribed to prevent coronary stent thrombosis.
Glycoprotein IIb/IIIa Inhibitors
Potent intravenous antiplatelet agents administered in unstable angina or NSTEMI to prevent final-pathway fibrinogen binding and platelet aggregation.
Intravenous Nitroglycerin in ACS
A continuous vasodilator infusion used in acute coronary syndrome to reduce cardiac preload, decrease myocardial wall tension, and relieve persistent ischemic chest pain.
Morphine Sulfate in ACS
An intravenous opioid administered for refractory chest pain that relieves severe discomfort, reduces preload and afterload through vasodilation, and decreases anxiety.
Beta-Adrenergic Blockers in ACS
Pharmacotherapy administered to decrease heart rate, reduce systemic blood pressure, attenuate myocardial contractility, and lower myocardial oxygen demand post-MI.
High-Dose Statin Therapy Post-ACS
The immediate administration of aggressive lipid-lowering medication (such as atorvastatin) to stabilize plaques and reduce future vascular events following an acute coronary event.
Nutritional Therapy for ACS
The dietary progression starting with NPO status during acute presentation, advancing to a diet low in sodium, saturated fat, and cholesterol.
Heart Failure (HF)
A clinical syndrome characterized by the inability of the heart to pump sufficient blood to meet the metabolic and oxygen demands of tissues and organs.
Leading Demographic for HF Admissions
Older adults over the age of 65, for whom heart failure represents the most common reason for inpatient hospital admission.
Primary Etiologies of Heart Failure
The two most prevalent underlying clinical causes of myocardial insult and subsequent heart failure: hypertension and coronary artery disease.
Cardiac Output (CO)
The volume of blood ejected by the heart per minute, serving as a primary indicator of systemic tissue perfusion.
Cardiac Output Mathematical Formula
The physiological equation defining cardiac output as the product of stroke volume and heart rate: CO=SV×HR.
Normal Adult Cardiac Output Range
The typical physiologic resting cardiac output volume in a healthy adult, measuring between 4 and 8 L/min.
Stroke Volume (SV)
The absolute volume of blood pumped out of the ventricle with each individual heartbeat.
Determinants of Stroke Volume
The three fundamental physiological properties that regulate stroke volume: preload, afterload, and myocardial contractility.
Preload
The volume of blood in the ventricles at the end of diastole, representing the initial stretch applied to myocardial muscle fibers prior to contraction.
Afterload
The resistance or systemic arterial pressure against which the left ventricle must pump to eject blood into circulation during systole.
Myocardial Contractility
The inherent force and velocity of myocardial fiber shortening independent of changes in preload or afterload.
Ejection Fraction (EF)
The percentage of total left ventricular end-diastolic blood volume ejected from the ventricle during each subsequent systolic contraction.
Normal Left Ventricular Ejection Fraction (LVEF)
The physiological normal range for resting left ventricular ejection fraction, established between 55% and 65%.
Heart Failure with Reduced Ejection Fraction (HFrEF)
A form of systolic heart failure characterized by impaired ventricular contractility and an ejection fraction generally below 40%.
Pathophysiology of HFrEF
A failure of the left ventricle to generate adequate systolic pressure to eject blood forward, causing blood to pool in the left atrium and back up into pulmonary vasculature.
Heart Failure with Preserved Ejection Fraction (HFpEF)
A form of diastolic heart failure wherein the left ventricle is stiff and noncompliant, impairing diastolic filling despite a normal ejection fraction (≥50%).
Diagnostic Criteria for HFpEF
The clinical diagnosis confirmed by clinical signs and symptoms of heart failure, normal LVEF on echocardiogram, and evidence of diastolic filling dysfunction.
Left-Sided Heart Failure
The most common form of heart failure, characterized by left ventricular dysfunction, retrograde blood pooling into pulmonary veins, and elevated pulmonary hydrostatic pressure.
Pulmonary Hydrostatic Pressure Elevation
The hemodynamic consequence of left ventricular failure where blood backing up from the left atrium forces fluid out of pulmonary capillaries into lung parenchyma.
Respiratory Manifestations of Left HF
Clinical pulmonary signs resulting from fluid backup into lungs, including dyspnea on exertion, orthopnea, paroxysmal nocturnal dyspnea, crackles, and tachypnea.
Right-Sided Heart Failure
Ventricular dysfunction characterized by the inability of the right ventricle to pump blood forward into pulmonary circulation, causing fluid backup into the systemic venous system.
Primary Etiology of Right-Sided HF
Left-sided heart failure, which causes chronic backward pulmonary venous congestion and secondary pulmonary hypertension that overworks the right ventricle.